Rinvask: Dosages and Ingredients | Full Prescribing Info

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Indications/Uses Dosage/Direction for Use Contraindications Special Precautions Adverse Reactions Drug Interactions MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Contents

Pitavastatin calcium hydrate.

Indications/Uses

Primary hyperlipidemia and mixed dyslipidemia; Heterozygous Familial Hypercholesterolemia (HeFH).

Dosage/Direction for Use

1-4 mg once daily. Initially 2 mg. Max dose: 4 mg daily.
Patients with moderate kidney impairment (GFR 30-59 mL/min/1.73 m²), severe kidney impairment (15-29 mL/min/1.73 m²) without hemodialysis, end stage of kidney impairment with hemodialysis: Initially 1 mg once daily, max: 2 mg once daily.
To be taken with or without meals.

Contraindications

Hypersensitivity. Patients with liver diseases. Concomitant use with cyclosporines. Pregnancy, lactation.

Special Precautions

Patients with predisposing factors of myopathy, ie. elderly (≥65 yr), kidney dysfunction, untreated hypothyroidism. Treatment should be discontinued if creatine kinase is increased or any suspected or diagnosed myopathy. Liver enzyme test should be performed before treatment or if any liver damage occur. Consume excessive alcohol.

Adverse Reactions

Rhabdomyolysis with myoglobinuria, acute kidney failure, myopathy.

View ADR Reporting Link

Drug Interactions

Cyclosporin, erythromycin, rifampicin, gemfibrozil, other fibrates, niacin.

MIMS Class

Dyslipidaemic Agents

ATC Classification

C10AA08 - pitavastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.

Regulatory Classification

Presentation/Packing

Form

Rinvask FC tab 2 mg

Packing/Price

3 × 10's

Rinvask

pitavastatin

Manufacturer:

Yarindo Farmatama